Multicenter study reveals acceptable efficacy and tolerability of carboplatin in advanced nasopharyngeal carcinoma, highlighting a feasible alternative for cisplatin-ineligible patients.
Carboplatin CCRT provided acceptable efficacy and tolerability profiles in real-world practice. Carboplatin should be considered as an alternative regimen, particularly in cisplatin-ineligible patients with LA-NPC treated with CCRT.
No takes yet. Share an insight, caveat, or question.
Dechaphunkul et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: